Evidence map›Paper›PMID 39350270›Full record

Trial reportStem cell research & therapy2024

Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up.

Zhixian Wu, Shulin Huang, Shasha Li, Jinquan Cai, Lianghu Huang, Weizhen Wu, Jin Chen, Jianming Tan

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01719640 (Autologous Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Infusion in Type 2 Diabetes Mellitus), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01719640 phase1 / phase2completednot on this map

Autologous Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Infusion in Type 2 Diabetes Mellitus

TypeinterventionalSponsorFuzhou General HospitalRan2011 to 2020Enrolled22ConditionsDiabetes Mellitus, Type 2Armsinfusion of MSCs, infusion MCs, insulin
3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Advancements in diabetes research and stem cell therapy: a concise review.Journal of diabetes and metabolic disorders · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhixian Wu *Organ Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China.
Shulin Huang *Endocrinology Department, The 900th Hospital of Joint Logistic Support Force, Fuzong Clinical College of Fujian Medical University, Fuzhou, P.R. China.
Shasha Li *Organ Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China.
Jinquan CaiOrgan Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China.
Lianghu HuangOrgan Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China.
Weizhen WuOrgan Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China.
Jin ChenOrgan Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China. kingchen81@qq.com.
Jianming TanOrgan Transplant Institute, The 900th Hospital of Joint Logistic Support Force (Fuzhou General Hospital), Fuzong Clinical College of Fujian Medical University, Fuzhou, 350025, P.R. China. tanjm156@xmu.edu.cn.ORCID 0000-0001-6968-4445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the long-term effects of combining bone marrow mesenchymal stem cells (MSCs) with mononuclear cells (MCs) in the treatment of type 2 diabetes mellitus (T2DM).

methodsT2DM patients were divided into the combination group (Dual MSC + MC, n = 33), the mononuclear cell group (MC-Only, n = 32) and the control group (Control, n = 31). All groups were treated with insulin and metformin. The Dual MSC + MC group additionally received MSC and MC infusion and the MC-Only group additionally received MC infusion. The patients were followed up for 8 years. The primary endpoint was the C-peptide area under the curve (C-p AUC) at 1 year. This study was registered with clinicaltrial.gov (NCT01719640).

resultsA total of 97 patients were included and 89 completed the follow-up. The area under the curve of C-peptide of the Dual MSC + MC group and the MC-Only group was significantly increased (50.6% and 32.8%, respectively) at 1 year. After eight years of follow-up, the incidence of macrovascular complications was 13.8% (p = 0.009) in the Dual MSC + MC group and 21.4% (p = 0.061) in the MC-Only group, while it was 44.8% in the Control group. The incidence of diabetic peripheral neuropathy (DPN) was 10.3% (p = 0.0015) in the Dual MSC + MC group, 17.9% (p = 0.015) in the MC-Only group, and 48.3% in the Control group.

conclusionsThe combination of MSC and MC therapy can reduce the incidence of chronic diabetes complications and improves metabolic control with mild side effects in T2DM patients.

Indexed as

Diabetes Mellitus, Type 2Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdultAgedCombined Modality TherapyC-PeptideFemaleFollow-Up StudiesHumansLeukocytes, MononuclearMaleMiddle AgedC-PeptideAutologousBone marrowDiabetes complicationsMesenchymal stem cellsMononuclear cellsType 2 diabetes mellitus

Identifiers

PMID39350270
PMCPMC11443831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.